Arrowhead Pharmaceuticals · 9 hours ago
Summer Intern, Process Validation
Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The Process Engineer Intern will support engineering and validation activities by developing process documentation and collaborating with process engineers and validation teams.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Develop program-specific process flow diagrams (PFDs) using tools such as Visio, including equipment identification and key process details
Measure and calculate material contacting surface areas of process equipment to support validation activities
Support process and cleaning validation calculations, including review and verification of data
Gather equipment information external vendors and collaborate with Process Engineers and Validation teams to extract required data
Document and write a standardized procedure outlining methods for calculating equipment surface area
Generate clear, organized reports and documentation to support validation campaigns
Collaborate with cross-functional teams to ensure accuracy and completeness of engineering and validation data
Qualification
Required
Currently enrolled student at an accredited university or college, with a minimum of two years completed toward a degree in Chemical Engineering, Chemistry, or a related scientific discipline
Excellent verbal and written communication skills, including comfort presenting in group settings
Strong organizational skills and ability to manage detailed, technical tasks
Proficiency in Microsoft Office applications
Preferred
Familiarity with process flow diagrams (PFDs) or engineering drawings
Experience using Visio or similar diagramming software
Interest in process engineering, validation, or pharmaceutical manufacturing
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Recent News
2026-01-08
Company data provided by crunchbase